Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Regulatory News (MXCT)

  • There is currently no data for MXCT

Holding(s) in Company

20 Sep 2024 17:02

RNS Number : 1162F
MaxCyte, Inc.
20 September 2024
 

TR-1: Notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:

MAXCYTE INC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

X

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

 X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify) iii:

3. Details of person subject to the notification obligation iv

Name

BlackRock, Inc.

City and country of registered office (if applicable)

Wilmington, DE, USA

4. Full name of shareholder(s) (if different from 3.) v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reached vi:

17/09/2024

6. Date on which issuer notified (DD/MM/YYYY):

18/09/2024

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B) vii

Resulting situation on the date on which threshold was crossed or reached

9.28%

0.46%

9.75%

10,263,382

Position of previous notification (if

applicable)

8.99%

0.74%

9.74%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rights ix

% of voting rights

Direct

(DTR5.1)

Indirect

 (DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

US57777K1060

9,769,682

9.28%

SUBTOTAL 8. A

9,769,682

9.28%

 

 

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

Securities Lending

N/A

N/A

493,700

0.46%

SUBTOTAL 8. B 1

493,700

0.46%

 

 

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Physical or cash

Settlement xii

Number of voting rights

% of voting rights

 

SUBTOTAL 8.B.2

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv

X

Name xv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

BlackRock, Inc.

Trident Merger, LLC

BlackRock Investment Management, LLC

BlackRock, Inc.

BlackRock Holdco 2, Inc.

BlackRock Financial Management, Inc.

BlackRock International Holdings, Inc.

BR Jersey International Holdings L.P.

BlackRock Holdco 3, LLC

BlackRock Cayman 1 LP

BlackRock Cayman West Bay Finco Limited

BlackRock Cayman West Bay IV Limited

BlackRock Group Limited

BlackRock Finance Europe Limited

BlackRock Investment Management (UK) Limited

BlackRock, Inc.

BlackRock Holdco 2, Inc.

BlackRock Financial Management, Inc.

BlackRock Holdco 4, LLC

BlackRock Holdco 6, LLC

BlackRock Delaware Holdings Inc.

BlackRock Institutional Trust Company, National Association

BlackRock, Inc.

BlackRock Holdco 2, Inc.

BlackRock Financial Management, Inc.

BlackRock Holdco 4, LLC

BlackRock Holdco 6, LLC

BlackRock Delaware Holdings Inc.

BlackRock Fund Advisors

4.43%

0.22%

4.66%

BlackRock, Inc.

BlackRock Holdco 2, Inc.

BlackRock Financial Management, Inc.

BlackRock, Inc.

BlackRock Holdco 2, Inc.

BlackRock Financial Management, Inc.

BlackRock International Holdings, Inc.

BlackRock Canada Holdings ULC

BlackRock Asset Management Canada Limited

BlackRock, Inc.

BlackRock Holdco 2, Inc.

BlackRock Financial Management, Inc.

BlackRock Capital Holdings, Inc.

BlackRock Advisors, LLC

BlackRock, Inc.

BlackRock Holdco 2, Inc.

BlackRock Financial Management, Inc.

BlackRock International Holdings, Inc.

BR Jersey International Holdings L.P.

BlackRock Holdco 3, LLC

BlackRock Cayman 1 LP

BlackRock Cayman West Bay Finco Limited

BlackRock Cayman West Bay IV Limited

BlackRock Group Limited

BlackRock Finance Europe Limited

BlackRock Advisors (UK) Limited

BlackRock, Inc.

Trident Merger, LLC

BlackRock Investment Management, LLC

Amethyst Intermediate, LLC

Aperio Holdings, LLC

Aperio Group, LLC

 

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional information xvi

 

BlackRock Regulatory Threshold Reporting Team Jana Blumenstein

020 7743 3650

 

 

Place of completion

12 Throgmorton Avenue, London, EC2N 2DL, U.K.

Date of completion

18 September 2024

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLFLFEEAFIIFIS
Date   Source Headline
26th Jun 20257:00 amRNSCancellation - Maxcyte Inc
25th Jun 20257:00 amRNSLast Day of Dealings on AIM
23rd Jun 20256:00 pmRNSMaxCyte
19th Jun 20257:00 amRNSResult of Annual General Meeting
12th Jun 20257:00 amRNSHolding(s) in Company
11th Jun 20257:00 amRNS-RMaxCyte and Ori Biotech Announce Collaboration
6th Jun 20259:33 amRNSHolding(s) in Company
5th Jun 20252:16 pmRNSHolding(s) in Company
2nd Jun 20255:14 pmRNSTotal Voting Rights
2nd Jun 20254:17 pmRNSHolding(s) in Company
29th May 20257:06 amRNSHolding(s) in Company
23rd May 20254:52 pmRNSHolding(s) in Company
23rd May 20254:26 pmRNSHolding(s) in Company
23rd May 20257:00 amRNSHolding(s) in Company
19th May 20256:05 pmRNSHolding(s) in Company
16th May 20253:12 pmRNSHolding(s) in Company
9th May 20257:00 amRNSFiling of Form 10-Q
8th May 20257:00 amRNSFirst Quarter 2025 Financial Results
2nd May 20254:40 pmRNSTotal Voting Rights
28th Apr 20257:00 amRNSFiling of definitive proxy statement
22nd Apr 20252:43 pmRNSHolding(s) in Company
22nd Apr 20252:37 pmRNSHolding(s) in Company
15th Apr 20255:00 pmRNSHolding(s) in Company
15th Apr 20257:00 amRNSProposed cancellation of trading on AIM
14th Apr 20259:17 amRNSHolding(s) in Company
10th Apr 20257:00 amRNSMaxCyte to Report Q1 2025 Results on May 7, 2025
8th Apr 20253:35 pmRNSHolding(s) in Company
1st Apr 20255:57 pmRNSTotal Voting Rights
26th Mar 202510:14 amRNSCorrection: Vesting of RSUs and PDMR Dealing
26th Mar 20257:00 amRNSVesting of RSUs and PDMR Dealing
25th Mar 202510:30 amRNSHolding(s) in Company
25th Mar 202510:28 amRNSHolding(s) in Company
25th Mar 202510:26 amRNSHolding(s) in Company
25th Mar 202510:22 amRNSHolding(s) in Company
24th Mar 20259:06 amRNSGrant of Options, RSUs and PSUs and PDMR Dealing
19th Mar 20252:07 pmRNSHolding(s) in Company
12th Mar 20257:01 amRNSFiling of Form 10-K for FY ended December 31, 2024
12th Mar 20257:00 amRNSQ4 & FY 2024 Financial Results
4th Mar 20253:38 pmRNSTotal Voting Rights
19th Feb 20253:23 pmRNSHolding(s) in Company
14th Feb 20255:05 pmRNSHolding(s) in Company
13th Feb 20254:12 pmRNSHolding(s) in Company
13th Feb 20252:52 pmRNSHolding(s) in Company
12th Feb 20257:00 amRNSStrategic Platform License with TG Therapeutics
7th Feb 20257:00 amRNSNotice of Results
4th Feb 20257:00 amRNSTotal Voting Rights
31st Jan 20253:18 pmRNSExercise of options and PDMR dealing
30th Jan 20257:00 amRNSMaxCyte® Acquires SeQure Dx
29th Jan 20253:05 pmRNSHolding(s) in Company
22nd Jan 20252:25 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.